Home / About PPME / News / Biosimilars approved in Europe

Biosimilars approved in Europe

Published: 2011-09-05

Last update: 11 October 2011

In the EU, a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via EMA and not nationally.

During 2005 to 2006, EMA developed guidelines for the approval of biosimilars via an abbreviated registration process.

Omnitrope was the first product approved in the EU as a biosimilar, in 2006 [1]. To date, EMA has approved 14 biosimilars within the product classes of human growth hormone, granulocyte stimulating factor and erythropoietin, for use in the EU, see Table 1.

Table 1: EMA approved biosimilars*

Product Name

Active Substance

Therapeutic Area

Authorisation Date

Manufacturer/Company Name

Abseamed

epoetin alfa

Kidney Failure Chronic Anemia Cancer

28/08/2007

Medice Arzneimittel Pütter GmbH & Co KG

Binocrit

epoetin alfa

Kidney Failure Chronic Anemia

28/08/2007

Sandoz GmbH

Biograstim

filgrastim

Hematopoietic Stem Cell Transplantation Neutropenia Cancer

15/09/2008

CT Arzneimittel GmbH

Epoetin alfa Hexal

epoetin alfa

Kidney Failure Chronic Anemia Cancer

28/08/2007

Hexal AG

Filgrastim Hexal

filgrastim

Neutropenia Cancer Hematopoietic Stem Cell Transplantation

06/02/2009

Hexal AG

Filgrastim Ratiopharm

filgrastim

Neutropenia Hematopoietic Stem Cell Transplantation Cancer

15/09/2008
Withdrawn on 3 May 2011

Ratiopharm GmbH

Nivestim

filgrastim

Hematopoietic Stem Cell Transplantation Cancer Neutropenia

08/06/2010

Hospira UK Ltd

Omnitrope

somatropin

Turner Syndrome Dwarfism
Pituitary Prader-Willi Syndrome

12/04/2006

Sandoz GmbH

Ratiograstim

filgrastim

Neutropenia
Hematopoietic Stem Cell Transplantation
Cancer

15/09/2008

Ratiopharm GmbH

Retacrit

epoetin zeta

Hematopoietic Stem Cell Transplantation Cancer Neutropenia

18/12/2007

Hospira UK Limited

Silapo

epoetin zeta

Chronic Anemia
Blood Transfusion Autologous
Cancer Kidney Failure

18/12/2007

Stada R & D AG

Tevagrastim

filgrastim

Neutropenia Cancer
Hematopoietic Stem Cell Transplantation

15/09/2008

Teva Generics GmbH

Valtropin

somatropin

Dwarfism Pituitary Turner Syndrome

24/04/2006

BioPartners GmbH

Zarzio

filgrastim

Cancer Hematopoietic Stem Cell Transplantation Neutropenia

06/02/2009

Sandoz GmbH

*Data collected on 12 May 2011

Source: www.gabionline.net

Last update: 2011-10-11 |  Go Back |  Print View

Designed by Zwebb. Powered by eZpublish